Astarte Medical Secures $7.6 Million In Series A-1 Financing To Advance Its Technology For Improving Preterm Infant Outcomes
Astarte Medical Secures $7.6 Million In Series A-1 Financing To Advance Its Technology For Improving Preterm Infant Outcomes
09/22/21, 1:50 PM
Money raised
$7.6 million
Round Type
series a
Astarte Medical, a clinical intelligence company leveraging data and digital tools to improve health outcomes in the first 1000 days, today announced it has secured $7.6 million in Series A-1 financing. Investors in the round include Viking Global Investors LP, Lunsford Capital, Ben Franklin Technology Partners, OCA Ventures, Next Act Fund, Capita3, Leatherneck Ventures, and Social Venture Circle. The Company will use the funds to scale the sales of NICUtrition®, its EMR-integrated, clinical decision support platform addressing critical, unmet needs in the NICU like malnutrition, suboptimal growth, and racial disparities in care.
Company Info
Additional Info
Astarte Medical is a clinical intelligence company using software and predictive analytics to improve outcomes in the first 1,000 days of life, from conception to age two, with an initial focus on preterm infants. NICUtrition® by Astarte Medical supports feeding protocols, practice and decision-making in the neonatal ICU with a suite of digital tools designed to standardize feeding, optimize nutrition and assess the provision of equitable care. Learn more at www.AstarteMedical.com.
This project is supported by the Ben Franklin Technology Partners of Southeastern PA, an initiative of the Pennsylvania Department of Community and Economic Development funded by the Ben Franklin Technology Development Authority.